查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2017508

嗜伊红性食道炎（EoE）：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

Eosinophilic Esophagitis (EoE) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 156 Pages | 商品交期: 2-3个工作天内

价格
简介目录

市场概览

  • 美国末期（EoE）治疗市场预计将从 2025 年的 2.71 亿美元成长到 2035 年的 3.7 亿美元，预测期内复合年增长率为 3.2% 至 3.5%。
  • 短期成长（2025-2030 年）相对强劲，这主要得益于生物製药的普及和诊断率的提高。
  • PPI 占据市场主导地位（占 36-40% 的份额），并且由于其成本效益和可及性，仍然是首选治疗方法。
  • 局部皮质类固醇（Fluticasone、Budesonide）合计占市场份额的 25-30%。
  • 生物製药（Dupixent/Dupilumab）是一个高成长领域，预计市场份额将从 2025 年的 4% 稳步增长到 2035 年的 4.6% 以上。
  • AK002（relenterimab）、tezeperumab 和 APT-1011 等新兴治疗方法预计将促进收入成长，到 2035 年总合将超过 7,000 万美元。
  • 虽然药物治疗是主要方法，但饮食疗法和支持性护理虽然不太普遍，但在临床上仍占有重要地位。

嗜伊红性食道炎（EoE）概述

嗜伊红性食道炎（EoE），常被称为“食道气喘”，是一种慢性免疫介导的2型发炎性疾病，其特征是食道黏膜中大量嗜酸性粒细胞浸润，导致进行性结构重塑和功能障碍。此病由Th2介导的免疫通路触发，并与气喘、过敏性鼻炎、湿疹和食物过敏等特异性疾病密切相关。内视镜切片检查可确诊，病灶局限于食道，且高倍视野下嗜酸性粒细胞数（eos/hpf）超过15个。

嗜酸性粒细胞性食道炎的临床症状随年龄而异。在儿童患者中，呕吐、腹痛、逆流和进食困难较为常见；而在青少年和成人患者中，吞嚥困难、食物滞留和胸部不适（通常与纤维性狭窄的改变有关）是典型症状。

这种疾病呈进行性发展，如果不加以适当治疗，可能会从发炎性狭窄转变为纤维性狭窄。

目前的治疗策略包括质子帮浦阻断剂（PPI）、局部皮质类固醇（如Budesonide和Fluticasone）、饮食疗法，以及用于中度至重度病例的生物製药（如度普利尤单抗）。对于难治性或重症患者，生物製药如度普利尤单抗（一种IL-4/IL-13抑制剂）透过靶向潜在的免疫通路，显着改善了治疗效果。

儘管治疗方法取得了进展，但嗜酸性粒细胞性食道炎仍然是一种慢性复发性疾病，需要长期管理，目前还没有根治性或缓解疾病的治疗方法。

主要亮点

  • 据估计，2025年美国新患者数为27,008例，预计到2035年将增加至28,897例。这一稳步增长反映了诊断技术的进步和人们对该疾病认识的提高。
  • 受影响的人数明显更多，预计将从 2025 年的 53,671 人增加到 2035 年的 57,423 人，这凸显了该疾病的慢性性质以及患者患病的长期过程。
  • 预计到 2025 年确诊患者人数为 46,693 人，到 2035 年将增至 49,958 人。这表明诊断率正在逐步提高，但仍表明患病率和诊断率之间存在差距。
  • 这种疾病在男性中更为常见，预计到 2035 年，男性患者人数将超过女性患者人数（比例为 2.2 比 1）。
  • EoE 影响范围很广，年龄范围很广，在青年和中年人（21-40 岁）中的发病率最高，但儿童病例也占据着重要的临床地位。
  • 大多数病例为中度，其次是重度病例和轻度病例。
  • 吞嚥困难是最常见的症状，2025 年有 29,948 名患者受其影响，预计到 2035 年将增加到 32,042 名患者。其次是腹痛/消化不良和食道结构併发症。

格式化和更新讯息

  • 详细报告（PDF）
  • 市场预测模型（基于微软Excel）
  • 流行病学数据（MS Excel，互动式工具）
  • 高阶主管洞察（PPT简报）
  • 其他功能：定期更新、自订和顾问支援。
  • 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

  • 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
  • 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
  • 未来十年市场收入和病患份额的预测是多少？
  • 哪些因素对市场趋势影响最大？
  • 受访专家对目前和新兴的治疗方法有何看法？
  • 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
  • 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
  • 为确保药物核准和顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

  • G8
    • 我们
    • EU5
      • 法国
      • 德国
      • 义大利
      • 西班牙
      • 英国
    • 日本
    • 中国

大公司

  • Sanofi
  • AstraZeneca
  • NexEos Diagnostics, Inc.
  • Celldex Therapeutics
  • Eupraxia Pharmaceuticals Inc.
  • Revolo Biotherapeutics
  • Celgene
  • Ellodi Pharmaceuticals, LP
  • Phathom Pharmaceuticals, Inc.
  • AQILION AB
  • Uniquity One（UNI）
  • Regeneron Pharmaceuticals

目录

第一章：主要调查结果及分析师说明

  • 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

  • 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

  • 重点
  • 发病率/盛行率
  • 已确诊并接受药物治疗的患者人数
  • 合併症
  • 其他相关患者群

第四章 市场规模及预测

  • 重点
  • 市场驱动因素与限制因素
  • 按药物类别分類的趋势
  • 各国具体趋势

第五章 竞争情势

  • 目前的治疗方法
    • 重点
    • 诊断和治疗过程/演算法
    • 主要治疗方法概述及KOL洞察
  • 新兴治疗方法
    • 重点
    • 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
    • 值得关注的早期研发管线

第六章：未满足的需求与TPP分析

  • 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
  • TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

简介目录

Eosinophilic Esophagitis (EoE) Market Outlook

Thelansis's "Eosinophilic Esophagitis (EoE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Eosinophilic Esophagitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Eosinophilic Esophagitis (EoE) Overview

Eosinophilic Esophagitis (EoE), often described as the "asthma of the esophagus," is a chronic, immune-mediated Type 2 inflammatory disease characterized by dense eosinophilic infiltration of the esophageal mucosa, leading to progressive structural remodeling and functional impairment. The disease is driven by Th2-mediated immune pathways and is strongly associated with atopic conditions such as asthma, allergic rhinitis, eczema, and food allergies. Diagnosis is confirmed via endoscopic biopsy demonstrating ≥15 eosinophils per high-power field (eos/hpf), localized to the esophagus.

EoE presents with age-dependent clinical manifestations: Pediatric patients commonly experience vomiting, abdominal pain, regurgitation, and feeding difficulties, while adolescents and adults typically present with dysphagia, food impaction, and chest discomfort, often linked to fibrostenotic changes.

The disease follows a progressive course, transitioning from inflammatory to fibrostenotic phenotypes if not adequately managed.

Current treatment strategies include proton pump inhibitors (PPIs), topical corticosteroids (e.g., budesonide, fluticasone), dietary management, and biologics (e.g., dupilumab) in moderate-to-severe cases. For patients with refractory or severe disease, biologic therapies such as dupilumab (IL-4/IL-13 inhibitor) have significantly advanced treatment by targeting the underlying immunological pathways.

Despite therapeutic advancements, EoE remains a chronic, relapsing condition requiring long-term management, with no curative or disease-modifying therapies currently available.

Key Highlights

  • The incident EoE population in the United States is estimated at 27,008 cases in 2025, increasing to 28,897 by 2035, reflecting a steady rise driven by improved diagnosis and awareness.
  • The prevalent population is significantly larger, projected to grow from 53,671 in 2025 to 57,423 by 2035, highlighting the chronic nature of the disease and long patient duration.
  • The diagnosed population is estimated at 46,693 in 2025, increasing to 49,958 by 2035, indicating gradual improvement in diagnosis rates but still suggesting a gap between prevalence and diagnosis.
  • A male predominance is observed, with male cases vs female cases increasing by 2035 (2.2:1 ratio).
  • EoE affects a broad age range, with the highest burden observed in young and middle-aged adults (21-40 years), though pediatric cases remain clinically significant.
  • Disease severity is largely skewed toward moderate cases, followed by severe and mild segments.
  • Dysphagia is the most common symptom, affecting 29,948 patients in 2025, increasing to 32,042 by 2035, followed by abdominal pain/dyspepsia and esophageal structural complications.

Market Overview

  • The EoE treatment market in the US is projected to grow from $271 million in 2025 to $370 million by 2035, reflecting a CAGR of 3.2-3.5% over the forecast period.
  • Short-term growth (2025-2030) is relatively stronger, driven by increased adoption of biologics and improved diagnosis rates.
  • PPIs dominate the market (36-40% share), remaining first-line therapy due to cost-effectiveness and accessibility.
  • Topical corticosteroids (fluticasone, budesonide) account for 25-30% combined share.
  • Biologics (Dupixent/dupilumab) represent a high-growth segment, with share increasing steadily from 4% in 2025 to 4.6%+ by 2035.
  • Emerging therapies such as AK002 (lirentelimab), tezepelumab, and APT-1011 contribute incremental revenue, collectively reaching $70M+ by 2035
  • Pharmacological therapies dominate, while dietary and supportive therapies contribute smaller shares but remain clinically relevant.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

  • Sanofi
  • AstraZeneca
  • NexEos Diagnostics, Inc.
  • Celldex Therapeutics
  • Eupraxia Pharmaceuticals Inc.
  • Revolo Biotherapeutics
  • Celgene
  • Ellodi Pharmaceuticals, LP
  • Phathom Pharmaceuticals, Inc.
  • AQILION AB
  • Uniquity One (UNI)
  • Regeneron Pharmaceuticals

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies - profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)